Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Ural, Mehmet; Üney, Kamil

doi:10.3390/antibiotics10101190

Cited by 6 publications

(5 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tolfenamic acid after IV administration in rainbow trout exhibited short t 1/2ʎz with 3.47 h, which was similar to that previously reported in mammals (1.57-6.09 h, Jaussaud et al, 1992;Tekeli et al, 2020) and birds (1.51-1.95 h, Cetin et al, 2022;Turk et al, 2021b), it was shorter than reported in turtles (17.55-38.92 h, Corum et al, 2019;Raweewan et al, 2020b). Fish are heterotherms and their metabolic rates are approximately 10 times lower than mammals (Van de Pol et al, 2017). In addition, the metabolic rate of the fish is affected by the water temperature, and the metabolic rate decreases at low water temperature (Corum et al, 2023).…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Corum,

Durna Corum,

Marin

et al. 2024

Veterinary Medicine & Sci

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough research on the mechanism and control of pain and inflammation in fish has increased in recent years, the use of analgesic drugs is limited due to the lack of pharmacological information about analgesic drugs. Tolfenamic acid is a non‐steroidal anti‐inflammatory drug and can be used in fish due to its low side effect profile and superior pharmacokinetic properties.ObjectivesThe pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid were investigated following single intravascular (IV), intramuscular (IM) and oral administration of 2 mg/kg in rainbow trout at 13 ± 0.5°C.MethodsThe experiment was carried out on a total of 234 rainbow trout (Oncorhynchus mykiss). Tolfenamic acid was administered to fish via IV, IM and oral route at a dose of 2 mg/kg. Blood samples were taken at 13 different sampling times until the 72 h after drug administration. The plasma concentrations of tolfenamic acid were quantified using high pressure liquid chromatography–ultraviolet (UV) and pharmacokinetic parameters were assessed using non‐compartmental analysis.ResultsThe elimination half‐life (t1/2ʎz) of tolfenamic acid for IV, IM and oral routes was 3.47, 6.75 and 9.19 h, respectively. For the IV route, the volume of distribution at a steady state and total body clearance of tolfenamic acid were 0.09 L/kg and 0.03 L/h/kg, respectively. The peak plasma concentration and bioavailability for IM and oral administration were 8.82 and 1.24 µg/mL, and 78.45% and 21.48%, respectively. The mean plasma protein binding ratio of tolfenamic acid in rainbow trout was 99.48% and was not concentration dependent.ConclusionsWhile IM route, which exhibits both the high plasma concentration and bioavailability, can be used in rainbow trout, oral route is not recommended due to low plasma concentration and bioavailability. However, there is a need to demonstrate the pharmacodynamic activity of tolfenamic acid in rainbow trout.

show abstract

Section: Discussionsupporting

confidence: 85%

“…In plasma samples obtained from healthy fish, the plasma protein binding ratio of tolfenamic acid was evaluated using ultrafiltration method (Ural & Uney, 2021 ). Plasma collected from fish that were not treated with drug was pooled.…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Corum,

Durna Corum,

Marin

et al. 2024

Veterinary Medicine & Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…They work by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing the normal replication of bacterial DNA and leading to irreversible damage, thus exhibiting antibacterial effects [ 4 ]. These compounds are widely used in the treatment of various bacterial infectious diseases in livestock and poultry due to their advantages such as long half-life, low plasma protein binding rate, strong bactericidal activity, ease of clinical use, and minimal side effects [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Danofloxacin in Gushi Chickens after Single Oral and Intravenous Administration

Chen

Li²,

Duan

et al. 2023

Metabolites

View full text Add to dashboard Cite

This study aimed to determine the pharmacokinetics of danofloxacin in Gushi chickens after a single oral (PO) and intravenous (IV) dose at 5 mg/kg body weight (BW). Thirty-two Gushi chickens, aged 20 weeks, were selected and divided into two groups at random, with each group consisting of 16 chickens, evenly distributed between males and females. Following danofloxacin administration, blood samples were taken at predetermined time intervals and the plasma was separated. The concentrations of danofloxacin in plasma were quantified by HPLC with a fluorescence detector. Then the concentrations versus time data were subjected to non-compartmental analysis (NCA) using Phoenix software (version: 8.1.0). After administering danofloxacin orally at a dose of 5 mg/kg BW to Gushi chickens, our results demonstrated that the peak concentration reached 0.53 μg/mL at 4 h. The half-life of absorption (t1/2ka) was determined to be 2.37 ± 1.60 h, and the bioavailability (F) was calculated as 40.12 ± 15.83%. For both oral and intravenous administration, the area under the concentration–time curve (AUC0-∞) was determined to be 4.72 ± 1.86 and 11.76 ± 3.25 h·µg/mL, respectively. The corresponding elimination half-life (t1/2λz) was measured as 11.24 ± 3.90 and 10.17 ± 3.72 h. Moreover, the mean residence time (MRT) was calculated as 10.20 ± 2.47 and 7.05 ± 1.97 h for these respective routes. Based on the calculated AUC/MIC ratio values, it can be inferred that the 5 mg/kg BW dosage of danofloxacin, whether administered orally or intravenously, is expected to effectively treat Escherichia coli and Pasteurella multocida infections in Gushi chickens.

show abstract

“…Moreover, the antibacterial efficacy of the three nanosystems before and after loading with danofloxacin will be evaluated. Danofloxacin is an antibiotic of the family of fluoroquinolones actives against most of the Gram-negative bacteria such as Escherichia coli, Klebsiella, and Salmonella, as well as some Gram-positive ones, including Staphylococcus aureus and Streptococcus pneumoniae [46]. Danofloxacin was selected due to its small size, broad spectrum effect and low minimal inhibitory concentration (MIC) [47].…”

Section: Introductionmentioning

confidence: 99%

Cu-Doped Hollow Bioactive Glass Nanoparticles for Bone Infection Treatment

et al. 2022

View full text Add to dashboard Cite

In search of new approaches to treat bone infection and prevent drug resistance development, a nanosystem based on hollow bioactive glass nanoparticles (HBGN) of composition 79.5SiO2-(18-x)CaO-2.5P2O5-xCuO (x = 0, 2.5 or 5 mol-% CuO) was developed. The objective of the study was to evaluate the capacity of the HBGN to be used as a nanocarrier of the broad-spectrum antibiotic danofloxacin and source of bactericidal Cu2+ ions. Core-shell nanoparticles with specific surface areas close to 800 m2/g and pore volumes around 1 cm3/g were obtained by using hexadecyltrimethylammonium bromide (CTAB) and poly(styrene)-block-poly(acrylic acid) (PS-b-PAA) as structure-directing agents. Flow cytometry studies showed the cytocompatibility of the nanoparticles in MC3T3-E1 pre-osteoblastic cell cultures. Ion release studies confirmed the release of non-cytotoxic concentrations of Cu2+ ions within the therapeutic range. Moreover, it was shown that the inclusion of copper in the system resulted in a more gradual release of danofloxacin that was extended over one week. The bactericidal activity of the nanosystem was evaluated with E. coli and S. aureus strains. Nanoparticles with copper were not able to reduce bacterial viability by themselves and Cu-free HBGN failed to reduce bacterial growth, despite releasing higher antibiotic concentrations. However, HBGN enriched with copper and danofloxacin drastically reduced bacterial growth in sessile, planktonic and biofilm states, which was attributed to a synergistic effect between the action of Cu2+ ions and danofloxacin. Therefore, the nanosystem here investigated is a promising candidate as an alternative for the local treatment of bone infections.

show abstract

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Cited by 6 publications

References 82 publications

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Pharmacokinetics of Danofloxacin in Gushi Chickens after Single Oral and Intravenous Administration

Cu-Doped Hollow Bioactive Glass Nanoparticles for Bone Infection Treatment

Contact Info

Product

Resources

About